AbbVie ABBV stock has risen around 5% since it announced robust first-quarter 2026 results on April 29. It beat estimates for ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

But is the stock a buy on the dip?

AbbVie Inc. (NYSE:ABBV) is a global biopharma company built around research and a fairly broad mix of treatments.

AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy according to analysts. AbbVie Inc. (NYSE:ABBV) announced on ...

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases ...

Dividend stocks can be a pillar for long-term investing, generating passive income and offering stability even during tough ...

AbbVie (ABBV) stock gains as the company raised its full-year earnings outlook despite a mixed performance in Q1 2026. Read ...

Johnson & Johnson boasts a vast portfolio and a rock-solid balance sheet. AbbVie's main growth pillars are posting impressive ...

AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson’s Icotyde, the first oral IL-23 inhibitor on the market. This ...